

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	X

\*FHK- Florida Healthy Kids

## Entresto (sacubitril/valsartan)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Quantity Limit
Entresto (sacubitril/valsartan)	May be subject to quantity limit

### APPROVAL CRITERIA

Requests for Entresto (sacubitril/valsartan) may be approved if the following criteria are met:

- I. Individual is using for the treatment of New York Heart Association (NYHA) class II, III, or IV heart failure symptoms; **AND**
- II. Individual has a left ventricular ejection fraction less than or equal to 35%.

Entresto (sacubitril/valsartan) may **not** be approved for any of the following:

- I. Individual is pregnant or wishing to become pregnant; **OR**
- II. Individual is breastfeeding; **OR**
- III. Individual will be utilizing an angiotensin-converting enzyme (ACE) inhibitor **OR** angiotensin receptor blocker (ARB) in combination with Entresto (sacubitril/valsartan); **OR**
- IV. Individual will be utilizing in combination with Tekturna (aliskiren)/Tekturna HCT (aliskiren/hydrochlorothiazide) and has a diagnosis of:
  - A. Diabetes; **OR**
  - B. Renal impairment (eGFR) < 60 mL/min/1.73 m<sup>2</sup>;

**OR**

- V. Individual has a history of hereditary angioedema or angioedema related to previous ACE inhibitor or ARB therapy; **OR**
- VI. Individual has severe hepatic impairment (Child-Pugh C); **OR**

**Note:** Entresto (sacubitril/valsartan) has a black box warning for use in pregnancy as it can cause injury and death to a developing fetus. When pregnancy is detected, Entresto

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	X

\*FHK- Florida Healthy Kids

should be discontinued and alternative treatments considered. If Entresto is considered lifesaving for the mother, she should be advised of the potential risk to the fetus.

State Specific Mandates		
State name	Date effective	Mandate details (including specific bill if applicable)
N/A	N/A	N/A

**Key References:**

Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2018. URL: <http://www.clinicalpharmacology.com>. Updated periodically.

DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: March 30, 2018

DrugPoints® System (electronic version). Truven Health Analytics, Greenwood Village, CO. Updated periodically.

Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2018; Updated periodically.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.